Results 81 to 90 of about 11,606 (196)

Hairy cell leukemia: A retrospective study on 11 patients in the Western of Iran

International Journal of Hematology-Oncology and Stem Cell Research, 2015
Background: Hairy cell leukemia (HCL) is a chronic B-cell lymphoid leukemia characterized by pancytopenia, splenomegaly, myelofibrosis and the presence in peripheral blood, bone marrow and spleen of atypical lymphoid cells with a hairy aspect.
Mehrdad Payandeh, Masoud Sadeghi, Edris Sadeghi   +2 more
doaj  

Complex Genetic Architecture in RASopathies: Constitutional PTPN11 and Mosaic RIT1 Pathogenic Variants Underlying Severe Noonan Syndrome With Adult‐Onset Acute Myeloid Leukemia

American Journal of Medical Genetics Part A, Volume 200, Issue 8, Page 1879-1883, August 2026.
ABSTRACT Noonan syndrome (NS) is a genetically heterogeneous disorder characterized by a broad spectrum of clinical features resulting from dysregulation of the RAS/MAPK pathway. Although complex genotypes are increasingly recognized in NS, cases harboring two distinct pathogenic variants in different NS genes remain extremely rare.
Francesco Prevedello, Dario Seif Ali, Chiara Piccolo, Chiara Rigon, Monica Forzan, Elena Tacchetto, Roberta Palmitessa, Davide Calosci, Leonardo Salviati, Carmela Gurrieri, Eva Trevisson   +10 more
wiley   +1 more source

Tumor‐infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions

Cancer, Volume 132, Issue 15, 1 August 2026.
Abstract In the past 15 years, immunotherapy has become a major strategy for cancer therapy. Tumor‐infiltrating lymphocyte (TIL) therapy has been under investigation for nearly four decades and received its first Food and Drug Administration approval in 2024, when lifileucel was approved for patients with previously treated metastatic melanoma.
Shen Li, Alexandra E. Rojek, Reid Shaw, Cristina O’Donoghue, J. Michael Millis, Daniel J. Olson   +5 more
wiley   +1 more source

Tumor Plasticity and Microenvironmental Crosstalk as Drivers of Metastasis and Therapy Resistance

MedComm, Volume 7, Issue 8, August 2026.
The graphical abstract is a schematic illustration of the bidirectional crosstalk between tumor plasticity and the tumor microenvironment (TME) in driving metastasis and therapy resistance. Tumor‐intrinsic factors such as genetic mutations and epigenetic reprogramming enable dynamic transitions between epithelial, mesenchymal, and cancer stem cell ...
Gunjan Dagar, Manisha Dagar, Ashna Gupta, Anju Surendranath, Suraja Kumar Das, Mohd Umar Rehmani, Mukesh Tanwar, Sameer Mirza, Muzafar A. Macha, Ammira S. Al‐Shabeeb Akil, Shahab Uddin, Mayank Singh, Ajaz A. Bhat   +12 more
wiley   +1 more source

Antibody–Drug Conjugates and Peptide–Drug Conjugates: Current Understandings and Future Perspectives

MedComm, Volume 7, Issue 8, August 2026.
The graphic summarizes the design principles, intracellular trafficking, clinical progress, challenges, and future directions of antibody–drug conjugates (ADCs) and peptide–drug conjugates (PDCs). ADCs consist of a tumor‐targeting antibody, a chemical linker, and a potent payload, whereas PDCs use peptide ligands to deliver cytotoxic, radionuclide, or ...
Ruxi Zheng, Shuiquan Li, Zhigang Zhang, Mengke Niu, Jing Fei, Jiaojiao Zhang, Jianwei Zhou, Kongming Wu, Ming Yi, Tianye Li   +9 more
wiley   +1 more source

N‐Terminal Variant p.Ala2Val in X‐Linked Dyskeratosis Congenita Gene (DKC1) Disrupts Its Post‐Translational Modification and Nucleolar Localization

Molecular Genetics &Genomic Medicine, Volume 14, Issue 8, August 2026.
Major symptoms of dyskeratosis congenita. Predicted nuclear localization site at N‐terminus of DKC1 protein. Comparison of nuclear localization for DKC1 showing normal localization for wild‐type versus disruption of localization for p.Ala2Val. ABSTRACT Background Dyskeratosis congenita (DKC) is typically characterized by the triad of abnormal cutaneous
Taimoor I. Sheikh, John B. Vincent
wiley   +1 more source

OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 8, Page 1318-1331, August 2026.
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta, Julia Steriopoulos, Vasiliki Economopoulos, Paradi Mirmirani, Vincent Piguet   +4 more
wiley   +1 more source

A Case of Slow Progressive Cutaneous Angiomatosis on a Cat Metatarsal Pad Treated by a Topical Beta‐Blocker

Veterinary Dermatology, Volume 37, Issue 4, Page 530-533, August 2026.
ABSTRACT A 5‐year‐old female cat presented with a purple depressed lesion on a metatarsal pad inducing ulceration and pain. Histopathological results revealed a non‐neoplastic vascular proliferation, a rare condition in cats. Topical beta‐blocker successfully prevented recurrence of ulceration.
Adrien Accard, Rita Bitar, Maria Dolores Sanchez, Philippe Blumstein, Olivier Albaric, Nora Bouhsina, Emmanuel Bensignor   +6 more
wiley   +1 more source

Ultrastructure of hairy cell leukemia [PDF]

Cancer, 1972
F N, Ghadially, L F, Skinnider
openaire   +2 more sources

Treatment for recurrent hairy cell leukemia.

Терапевтический архив, 2012
Aim. To give data on the frequency of recurrent hairy cell leukemia (HCL) and to characterize the immediate and late results of its treatment in this group of patients. Materials and methods.
L S Al'-Radi, A V Pivnik, B V Zingerman, S K Kravchenko   +3 more
doaj